- Modern Pharmaceutical Company (MPC) is proud to support the distribution of Casgevy, a pioneering gene therapy for sickle cell disease. As the first approved treatment of its kind in the UAE, this marks a major milestone in advanced healthcare delivery. In this Q&A, Dr. Khaled Abdul Aal shares insights on how MPC prepared for this important advancement and its broader impact on healthcare in the region.
Dr. Khaled Abdul Aal
CEO PharmaConsumer Division
What does the launch of Casgevy mean for sickle cell patients in the UAE and the region?
Dr. Khaled: Casgevy offers new hope for patients living with sickle cell disease—a genetic condition that has long had limited treatment options. This gene therapy has the potential to be curative, not just palliative. For patients in the UAE and the wider region, this means access to advanced care that can greatly improve quality of life and long-term outcomes.
How has MPC prepared to support the distribution of this breakthrough gene therapy?
Dr. Khaled: Supporting a therapy of this kind required detailed preparation. Our supply chain is fully equipped to meet the demands of temperature-sensitive and high-value treatments. We trained our teams to manage every stage of the process and aligned closely with regulators and customs. We also carried out successful mock shipments, which helped us validate the entire logistics flow before patient onboarding began.
What challenges did MPC face in bringing this treatment to market, and how were they overcome?
Dr. Khaled: Introducing gene therapy to the region came with regulatory and logistical challenges. From approvals to last-mile delivery, every step had to meet strict global standards. Through early planning, strong collaboration, and the dedication of our internal teams, we ensured the process ran smoothly. Open communication and shared responsibility played a key role in staying on course.
How does this reflect MPC’s approach to innovation and patient care?
Dr. Khaled: Innovation is at the core of how we operate at MPC. Supporting access to gene therapy is a clear example that we’re not just delivering products; we’re helping bring next-generation treatments to patients who need them. By building the right systems, working closely with partners, and staying ahead of what’s next in healthcare, we’re making sure that patients across the UAE and the region benefit from the latest advancements.
 is proud to support the distribution of Casgevy, a pioneering gene therapy for sickle cell disease. As the first approved treatment of its kind in the UAE, this marks a major milestone in advanced healthcare delivery.){kind=link}